The anti-VEGF antibody bevacizumab (Avastin) has recently completed large-scale phase III trials in advanced colorectal carcinoma (Kabbinavar et al, 2003) (Hurwitz et al, 2004). This evidence concerns the gene VEGFA and colorectal carcinoma.